New horizons in lung cancer management through ATR/CHK1 pathway modulation-Reference-Cited by-同舟云学术

New horizons in lung cancer management through ATR/CHK1 pathway modulation

Published:2023-10 Issue:19 Volume:15 Page:1807-1818
ISSN:1756-8919
Container-title:Future Medicinal Chemistry
language:en
Short-container-title:Future Medicinal Chemistry

Author:

Thapa Riya¹^ORCID,Afzal Obaid²^ORCID,Bhat Asif Ahmad¹^ORCID,Goyal Ahsas³^ORCID,Alfawaz Altamimi Abdulmalik Saleh²^ORCID,Almalki Waleed Hassan⁴^ORCID,Alzarea Sami I⁵^ORCID,Kazmi Imran⁶^ORCID,Singh Sachin Kumar⁷⁸,Dua Kamal⁸⁹^ORCID,Thangavelu Lakshmi¹⁰^ORCID,Gupta Gaurav¹¹¹^ORCID

Affiliation:

1. School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India

2. Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al Kharj, 11942, Saudi Arabia

3. Institute of Pharmaceutical Research, GLA University, U.P., India

4. Department of Pharmacology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia

5. Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Al-Jouf, Saudi Arabia

6. Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia

7. School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, India

8. Faculty of Health, Australian Research Centre in Complementary & Integrative Medicine, University of Technology, Sydney, Ultimo, NSW, 2007, Australia

9. Discipline of Pharmacy, Graduate School of Health, University of Technology, Sydney, Ultimo-NSW, 2007, Australia

10. Center for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical & Technical Sciences, Saveetha University, India

11. School of Pharmacy, Graphic Era Hill University Dehradun, 248007, India

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling has contributed to a new classification of lung cancer, driving advancements in research and therapy. The ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway plays a crucial role in maintaining genomic stability, and its activation has been linked to the development of lung cancer, drug resistance and poor prognosis. Clinical and preclinical studies have demonstrated promising results in targeting this pathway. ATR and CHK1 are proteins that collaborate to repair DNA damage caused by radiation or chemotherapy. ATR/CHK1 inhibitors are currently under investigation in preclinical and clinical trials. This article explores the ATR/CHK1 pathway and its potential for treating lung cancer.

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Link

https://www.future-science.com/doi/pdf/10.4155/fmc-2023-0164

Reference80 articles.

1. Polysaccharide-Based Nanomedicines Targeting Lung Cancer

2. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives

3. Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms

4. Molecular Pathology of Lung Cancer

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The paradox of autophagy in cancer: NEAT1's role in tumorigenesis and therapeutic resistance;Pathology - Research and Practice;2024-10

2. MicroRNA-21 (miR-21) in breast cancer: From apoptosis dysregulation to therapeutic opportunities;Pathology - Research and Practice;2024-10

3. Non-coding RNAs as key regulators of Gasdermin-D mediated pyroptosis in cancer therapy;Pathology - Research and Practice;2024-09

4. GAS5 lncRNA: A biomarker and therapeutic target in breast cancer;Pathology - Research and Practice;2024-08

5. Harnessing pyroptosis for lung cancer therapy: The impact of NLRP3 inflammasome activation;Pathology - Research and Practice;2024-08